129 related articles for article (PubMed ID: 31546021)
1. A unique multidrug nanomedicine made of squalenoyl-gemcitabine and alkyl-lysophospholipid edelfosine.
Rodríguez-Nogales C; Sebastián V; Irusta S; Desmaële D; Couvreur P; Blanco-Prieto MJ
Eur J Pharm Biopharm; 2019 Nov; 144():165-173. PubMed ID: 31546021
[TBL] [Abstract][Full Text] [Related]
2. Squalenoyl-gemcitabine/edelfosine nanoassemblies: Anticancer activity in pediatric cancer cells and pharmacokinetic profile in mice.
Rodríguez-Nogales C; Mura S; Couvreur P; Blanco-Prieto MJ
Int J Pharm; 2020 May; 582():119345. PubMed ID: 32311470
[TBL] [Abstract][Full Text] [Related]
3. Interfacial behavior of PEGylated lipids and their effect on the stability of squalenoyl-drug nanoassemblies.
Bekkara-Aounallah F; Ambike A; Gref R; Couvreur P; Rosilio V
Int J Pharm; 2014 Aug; 471(1-2):75-82. PubMed ID: 24811925
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies.
Maksimenko A; Caron J; Mougin J; Desmaële D; Couvreur P
Int J Pharm; 2015 Mar; 482(1-2):38-46. PubMed ID: 25448549
[TBL] [Abstract][Full Text] [Related]
5. Anticancer efficacy of squalenoyl gemcitabine nanomedicine on 60 human tumor cell panel and on experimental tumor.
Reddy LH; Renoir JM; Marsaud V; Lepetre-Mouelhi S; Desmaële D; Couvreur P
Mol Pharm; 2009; 6(5):1526-35. PubMed ID: 19634915
[TBL] [Abstract][Full Text] [Related]
6. Interaction of an amphiphilic squalenoyl prodrug of gemcitabine with cellular membranes.
Bildstein L; Pili B; Marsaud V; Wack S; Meneau F; Lepêtre-Mouelhi S; Desmaële D; Bourgaux C; Couvreur P; Dubernet C
Eur J Pharm Biopharm; 2011 Nov; 79(3):612-20. PubMed ID: 21784150
[TBL] [Abstract][Full Text] [Related]
7. Combinatorial Nanomedicine Made of Squalenoyl-Gemcitabine and Edelfosine for the Treatment of Osteosarcoma.
Rodríguez-Nogales C; Moreno H; Zandueta C; Desmaële D; Lecanda F; Couvreur P; Blanco-Prieto MJ
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32674353
[TBL] [Abstract][Full Text] [Related]
8. Preclinical toxicology (subacute and acute) and efficacy of a new squalenoyl gemcitabine anticancer nanomedicine.
Reddy LH; Marque PE; Dubernet C; Mouelhi SL; Desmaële D; Couvreur P
J Pharmacol Exp Ther; 2008 May; 325(2):484-90. PubMed ID: 18258784
[TBL] [Abstract][Full Text] [Related]
9. Biomimetic nanoassemblies of 1-O-octodecyl-2-conjugated linoleoyl-sn-glycero-3-phosphatidyl gemcitabine with phospholipase A
Zuo J; Tong L; Du L; Yang M; Jin Y
Colloids Surf B Biointerfaces; 2017 Apr; 152():467-474. PubMed ID: 28187380
[TBL] [Abstract][Full Text] [Related]
10. Novel nanoassemblies composed of squalenoyl-paclitaxel derivatives: synthesis, characterization, and biological evaluation.
Dosio F; Reddy LH; Ferrero A; Stella B; Cattel L; Couvreur P
Bioconjug Chem; 2010 Jul; 21(7):1349-61. PubMed ID: 20597546
[TBL] [Abstract][Full Text] [Related]
11. Decoration of Squalenoyl-Gemcitabine Nanoparticles with Squalenyl-Hydroxybisphosphonate for the Treatment of Bone Tumors.
Rodríguez-Nogales C; Desmaële D; Sebastián V; Couvreur P; Blanco-Prieto MJ
ChemMedChem; 2021 Dec; 16(24):3730-3738. PubMed ID: 34581019
[TBL] [Abstract][Full Text] [Related]
12. Liposomal squalenoyl-gemcitabine: formulation, characterization and anticancer activity evaluation.
Pili B; Reddy LH; Bourgaux C; Lepêtre-Mouelhi S; Desmaële D; Couvreur P
Nanoscale; 2010 Aug; 2(8):1521-6. PubMed ID: 20820745
[TBL] [Abstract][Full Text] [Related]
13. Magnetoresponsive squalenoyl gemcitabine composite nanoparticles for cancer active targeting.
Arias JL; Reddy LH; Couvreur P
Langmuir; 2008 Jul; 24(14):7512-9. PubMed ID: 18540685
[TBL] [Abstract][Full Text] [Related]
14. Squalene based nanocomposites: a new platform for the design of multifunctional pharmaceutical theragnostics.
Arias JL; Reddy LH; Othman M; Gillet B; Desmaële D; Zouhiri F; Dosio F; Gref R; Couvreur P
ACS Nano; 2011 Feb; 5(2):1513-21. PubMed ID: 21275408
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic modalities of squalenoyl nanocomposites in colon cancer: an ongoing search for improved efficacy.
Maksimenko A; Alami M; Zouhiri F; Brion JD; Pruvost A; Mougin J; Hamze A; Boissenot T; Provot O; Desmaële D; Couvreur P
ACS Nano; 2014 Mar; 8(3):2018-32. PubMed ID: 24555414
[TBL] [Abstract][Full Text] [Related]
16. Squalenoyl nucleoside monophosphate nanoassemblies: new prodrug strategy for the delivery of nucleotide analogues.
Caron J; Reddy LH; Lepêtre-Mouelhi S; Wack S; Clayette P; Rogez-Kreuz C; Yousfi R; Couvreur P; Desmaële D
Bioorg Med Chem Lett; 2010 May; 20(9):2761-4. PubMed ID: 20363623
[TBL] [Abstract][Full Text] [Related]
17. Improving the antitumor activity of squalenoyl-paclitaxel conjugate nanoassemblies by manipulating the linker between paclitaxel and squalene.
Caron J; Maksimenko A; Wack S; Lepeltier E; Bourgaux C; Morvan E; Leblanc K; Couvreur P; Desmaële D
Adv Healthc Mater; 2013 Jan; 2(1):172-85. PubMed ID: 23213041
[TBL] [Abstract][Full Text] [Related]
18. A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types.
Reddy LH; Dubernet C; Mouelhi SL; Marque PE; Desmaele D; Couvreur P
J Control Release; 2007 Dec; 124(1-2):20-7. PubMed ID: 17878060
[TBL] [Abstract][Full Text] [Related]
19. A unique squalenoylated and nonpegylated doxorubicin nanomedicine with systemic long-circulating properties and anticancer activity.
Maksimenko A; Dosio F; Mougin J; Ferrero A; Wack S; Reddy LH; Weyn AA; Lepeltier E; Bourgaux C; Stella B; Cattel L; Couvreur P
Proc Natl Acad Sci U S A; 2014 Jan; 111(2):E217-26. PubMed ID: 24385587
[TBL] [Abstract][Full Text] [Related]
20. Transmembrane diffusion of gemcitabine by a nanoparticulate squalenoyl prodrug: an original drug delivery pathway.
Bildstein L; Dubernet C; Marsaud V; Chacun H; Nicolas V; Gueutin C; Sarasin A; Bénech H; Lepêtre-Mouelhi S; Desmaële D; Couvreur P
J Control Release; 2010 Oct; 147(2):163-70. PubMed ID: 20691740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
